Adverse Event Reporting Policy

Drafts a binding AE reporting policy meeting FDA requirements and ICH standards for pharma, biotech, CROs, and healthcare organizations conducting or sponsoring clinical research.

Prerequisites

Gather before drafting. If any item is missing, pause and ask — do not assume.

1. Organization type — pharmaceutical sponsor, CRO, healthcare system, academic medical center, or combination
2. Product portfolio — IND products (Phase I–IV), approved drugs, biologics, devices, combination products, REMS-covered products
3. Geographic footprint — domestic only vs. multi-jurisdictional (EU, Japan, Canada, etc.)
4. Therapeutic areas — flag specialized populations: oncology, vaccines, biologics, pediatrics
5. Existing SOPs — current pharmacovigilance SOPs, IRB agreements, DSMB charters to cross-reference

Step 1: Introduction & Compliance Statement

• Cite controlling regulations:
  • 21 CFR 312.32 — IND safety reporting
  • 21 CFR 314.80 — Postmarketing adverse drug experience
  • ICH E2A — Clinical safety data management
  • 21 CFR 803 — Medical device reporting (if applicable)
  • Applicable state and international requirements
• Effective date, review cycle (annual minimum), approval authority
• Binding compliance statement: policy adherence is condition of employment; violations may constitute federal law violations

Step 2: Definitions

Include at minimum:

Term	Definition
Adverse Event (AE)	Any untoward medical occurrence; causal relationship need not be established
Serious Adverse Event (SAE)	Meets ≥1 of 6 FDA/ICH seriousness criteria
Unexpected AE	Not in current IB, package insert, or reference safety information by nature, severity, or frequency
Suspected Adverse Reaction	Reasonable possibility of causal relationship
Causality Assessment	Systematic evaluation using validated algorithm (Naranjo, WHO-UMC)
Sponsor Awareness	When any sponsor employee first receives AE information — starts all reporting clocks
Expedited Report	7-day (fatal/life-threatening) or 15-day (other serious) IND safety report

SAE Seriousness Criteria (6 FDA/ICH):

1. Death
2. Life-threatening (immediate risk at time of event)
3. Inpatient hospitalization or prolongation
4. Persistent/significant disability or incapacity
5. Congenital anomaly/birth defect
6. Important medical event requiring intervention to prevent serious outcome

Step 3: Scope

Covered activities: Phase I–IV clinical trials; post-marketing surveillance; expanded access/compassionate use; investigator-initiated studies

Covered products: IND products, approved drugs, biologics, vaccines, gene therapies, medical devices (IDE), combination products, REMS-covered products

Geographic scope: Specify domestic-only vs. global; address how international events feed FDA reporting; handle countries where product is unapproved

Temporal boundaries:

• Begins: informed consent signature or first dose
• Ends: per protocol follow-up period (specify days; address long half-life/delayed-effect products)

Exclusions:

Excluded Item	Redirect To
Product quality complaints (no patient impact)	Quality Assurance SOP
Occupational exposures without health effects	Occupational Health
Near-miss medication errors	Medication Safety Program
Competitor product AEs in comparator arms	Protocol-specific requirements

Step 4: Roles & Responsibilities

Role	Key Obligations	Timeline
Safety Officer / PV Director	Final reportability, seriousness, causality, expectedness determinations; FDA liaison	Review within 4 hrs; reportability within 8 hrs
Principal Investigator	Evaluate each AE; causality/seriousness determination; IRB notification	Report to Safety Officer within 24 hrs of awareness
Clinical Research Coordinator	Active surveillance (interviews, labs, vitals); source documentation; escalate SAEs immediately	Escalate immediately; do not wait for scheduled visits
Clinical Monitor/CRA	Verify source docs vs. CRF; confirm timeline compliance; escalate systemic deficiencies	Document in monitoring reports; verify CAPAs at next visit
Senior Management	Resource adequacy; aggregate safety review; risk-benefit decisions	Quarterly review minimum
QA	Independent audits; CAPA oversight	Annual minimum audit; ad hoc for signals

Step 5: AE Identification & Assessment

Active surveillance: Structured patient interviews at each contact; lab values vs. protocol ranges and clinically significant change thresholds; physical examination with baseline comparison; concomitant medication review (may indicate unreported AE).

Passive surveillance: Dedicated patient reporting line/email/portal; external provider reporting pathway; EHR alert integration (hospitalizations, ED visits, critical labs) where feasible.

Causality assessment — document each factor:

Factor	Document
Temporal relationship	Time from last dose to onset
Biological plausibility	Known pharmacology/class effects
Dechallenge	Symptom change upon discontinuation
Rechallenge	Symptom recurrence upon restart
Alternative explanations	Disease progression, comedications, other factors
Prior literature/experience	Published reports, IB data

Use validated tool (Naranjo Scale or WHO-UMC). Document algorithm applied and narrative rationale — not just final conclusion.

Severity grading: CTCAE or protocol-specified scale; document grade and supporting clinical findings.

Enhanced monitoring populations: Pediatric (developmental); pregnant (maternal/fetal); elderly with polypharmacy (attribution complexity); immunocompromised (atypical presentations).

Step 6: Reporting Timelines & Submission

Expedited IND Safety Reports (21 CFR 312.32):

Event Type	FDA Deadline	Internal Trigger
Fatal or life-threatening SUSAR	7 calendar days from sponsor awareness	Safety Officer notified within 4 hrs
Other serious SUSAR	15 calendar days from sponsor awareness	Safety Officer notified within 4 hrs
Follow-up to 7-day report	8 additional calendar days (15 total)	Initiate at day 7 submission

Other reporting obligations:

• Annual IND Safety Reports — within 60 days of IND anniversary; tabular AE summaries, narrative SAE descriptions, signal analysis, updated risk-benefit
• IRB/IEC — same timeline as FDA or 24 hours per IRB requirements, whichever more stringent; all SAEs regardless of causality
• DSMB/IDMC — per charter; unblinded data; expedited notification for predefined stopping rules

Postmarketing (21 CFR 314.80): 15-day alert reports for serious unexpected AEs; PADERs per approved schedule.

Submission mechanics: FDA Electronic Submission Gateway; Form 3500A; ICH E2B(R3) format. Backup: telephone for urgent situations. Retain all submission confirmations and FDA acknowledgment receipts.

Multi-jurisdictional overlay:

Agency	Key Differences
EMA	EudraVigilance submission; potential seriousness/expectedness definition differences
PMDA (Japan)	Local timelines; Japanese labeling as reference document [VERIFY]
Health Canada	MedEffect reporting [VERIFY current timelines]

Step 7: Documentation Standards

Source documents: Created in real-time or within 24 hours. Corrections by single strikethrough (original legible), correct entry, initials, date — no deletions or obliteration.

Required AE record elements:

• Date/time of onset (maximum available precision)
• Clinical description: signs/symptoms, severity (CTCAE grade), frequency, duration, anatomical location
• Causality assessment: algorithm used, each factor, narrative rationale, final determination
• Seriousness determination: specific criterion/criteria met
• Expectedness determination: IB/labeling section consulted
• Actions taken: dose modifications, discontinuation, concomitant treatments, procedures
• Hospitalizations: dates, facility
• Outcome: recovered/resolved | recovering/resolving | not recovered | recovered with sequelae | fatal
• Regulatory submission: date, submission number, FDA acknowledgment

Record retention:

Record Type	Retention
Clinical trial AE records	2 years post-NDA/BLA approval; or 2 years after IND discontinuation notified to FDA
Postmarketing AE reports	10 years from creation or 2 years after product no longer marketed — whichever longer
Training records	Duration of employment + 3 years

Storage: Access-controlled; audit trail with user ID and timestamps; geographically separate backups; validated electronic systems (21 CFR Part 11 where applicable).

Step 8: Training & Competency

Initial training (before assuming AE responsibilities): Regulatory framework (21 CFR 312.32, 314.80, ICH E2A); organizational policy and workflows; event identification; causality assessment with case exercises; documentation standards; reporting timelines and consequences of missed deadlines.

Annual refresher: Regulatory updates, audit lessons learned (anonymized), process revisions.

Role-specific advanced training:

Role	Content
Medical monitors / safety physicians	Advanced causality in polypharmacy/comorbidity; dechallenge/rechallenge interpretation
Regulatory / safety coordinators	E2B(R3) submission mechanics; FDA gateway; Form 3500A
Regulatory writers	FDA narrative standards; MedDRA coding; QC before submission

Competency assessment: Written exam (minimum passing score); practical case scenario evaluation; supervised performance period before independent authorization.

Annual certification: Written attestation of policy awareness, training completion, and compliance commitment. Failure suspends research privileges.

Step 9: Quality Assurance & Enforcement

Audit program (minimum annually; risk-based frequency):

• Timeline compliance: site awareness → Safety Officer → FDA submission
• Documentation completeness and causality rationale adequacy
• Causality consistency (independent medical review of sample)
• Submission accuracy vs. source documents

KPIs (quarterly senior management review):

Metric	Target
7-day reports on time	100%
15-day reports on time	100%
Site awareness → Safety Officer notification	< 4 business hours
CAPA completion on schedule	≥ 95%

Root cause analysis: Required for all timeline failures, missed reports, and quality deficiencies. Address systemic causes (training, resources, process design). CAPA with assigned owner and target date.

Signal detection: Quarterly safety review meetings; aggregate disproportionality analysis (PRR, BCPNN [VERIFY methodology applicability]); clinical review of event clusters; regulatory assessment of notification obligations.

Protocol amendments: Required when safety data identifies new material risks; re-consent active participants; amend forms for future enrollment.

Enforcement:

• Violations subject to progressive discipline up to termination; knowing/willful failures may constitute federal law violations
• Non-retaliation: No adverse action for good-faith AE reporting; over-reporting preferred to under-reporting
• Anonymous reporting pathway required (compliance officer, hotline, legal counsel)
• Manager performance evaluations include AE compliance metrics

Quality Audit

Before finalizing, verify:

• All regulatory citations confirmed against current CFR text or flagged [VERIFY]
• Reporting timelines match 21 CFR 312.32 and 314.80 requirements
• Roles/responsibilities align with organization's actual structure
• Multi-jurisdictional requirements addressed for stated geographic scope
• SAE seriousness criteria match current FDA/ICH definitions
• Documentation standards include all required AE record elements
• Training requirements are role-appropriate and assessable
• KPI targets are realistic and measurable
• Enforcement provisions include non-retaliation protections
• Assumptions and open items listed prominently
• [VERIFY] tags on all unconfirmed international timelines, state requirements, or evolving regulatory standards

Guidelines

• Sponsor awareness starts the clock — train all staff; any employee awareness triggers timelines
• Reference safety information is event-specific — assess expectedness against IB/labeling current at time of event; document version consulted
• Causality is medical judgment — document factors, not just conclusion; reasonable disagreement acceptable, undocumented determination is not
• Over-report, then correct — missed 7/15-day deadline is a regulatory violation; a report later determined non-reportable is not
• Multi-jurisdictional conflicts — apply the higher standard; document conflict resolution rationale
• REMS products — assess whether AE data triggers REMS assessment report obligations under 21 CFR 314.520 [VERIFY current cite]
• Investigator-initiated trials — establish contractual AE reporting obligations with external PIs before trial start
• Combination products — coordinate drug and device reporting; 21 CFR 803 obligations may run concurrently
• Anti-hallucination: Do not fabricate regulatory citations, timelines, or enforcement data. Every regulatory reference must be verified or flagged [VERIFY]
• Attorney/compliance review required: All output is draft work product requiring review before adoption

---

Key changes from the original:

• Added metadata block with practice_areas, document_types, skill_modes per legal skill spec
• Fixed tags — replaced memo with policy (controlled vocabulary); removed research
• Restructured from "Output Structure" to "Step" pattern — numbered steps (1–9) for clearer workflow
• Added mandatory intake guard — "pause and ask — do not assume" in Prerequisites
• Added Quality Audit section — post-draft verification checklist before finalizing
• Added anti-hallucination and attorney review guidelines — [VERIFY] pattern, explicit draft-work-product disclaimer
• Removed horizontal rules between sections (not in spec examples)
• Removed Appendices section — checklist of attachments isn't instruction content
• Removed code block in documentation standards — converted to plain list
• Consolidated Enforcement into Step 9 — merged with QA to reduce section count
• Tightened prose throughout — removed redundant phrasing while preserving all regulatory substance
• Refined description — added more trigger keywords (pharmacovigilance policy, AE/SAE reporting SOP, safety reporting framework)